Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | ALPL | P05186 | 13/20 | 0.46 |
| ▸ | CA12 | O43570 | 5/20 | 0.46 |
| ▸ | RPA1 | P27694 | 1/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29663537 | 0.93 | HCAR2 (0.51) | HCAR3HCAR2TP53ALPLCA12 | |
| SCHEMBL15566952 | 0.93 | HCAR2 (0.47) | HCAR3HCAR2TP53ALPLCA12 | |
| SCHEMBL29663557 | 0.91 | KMO (0.49) | HCAR3HCAR2TP53ALPLCA12 | |
| SCHEMBL23293381 | 0.88 | HCAR3 (0.43) | HCAR3HCAR2TP53ALPLCA12 | |
| SCHEMBL27028208 | 0.88 | ALPL (0.43) | HCAR3HCAR2TP53ALPLCA12 | |
| SCHEMBL4058634 | 0.83 | PLA2G10 (0.43) | HCAR3HCAR2TP53ALPL | |
| SCHEMBL16619736 | 0.80 | CHEK1 (0.51) | HCAR2 | |
| SCHEMBL19284393 | 0.79 | MAPK1 (0.57) | ALPL | |
| SCHEMBL1281530 | 0.75 | ALPL (0.53) | TP53ALPLKDM4E | |
| SCHEMBL27417312 | 0.73 | MAPK1 (0.54) | HCAR2ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869019-B1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PROD INC (US) | 2014-08-27 | — | — | EP | claimed |
| US-8426404-B2 | e.g. 3-[1-(6-Amino-pyrimidin-4-yl)-1H-benzoimidazol-2-ylamino]-4-methyl-N-[4-(2-methyl-imidazol-1-yl)-3-trifluoromethyl-phenyl]-benzamide; receptor and non-receptor tyrosine kinases and serine/threonine kinases inhibitor; antiproliferative agent; immune and nervous system disorders | NOVARTIS AG (CH) | 2013-04-23 | — | — | US | claimed |
| EP-1899296-B1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2010-11-17 | — | — | EP | claimed |
| US-7812040-B2 | such as 3-(3-Acetyl-phenyl)-1-[3-(3-chloro-4-pyrrolidin-1-ylmethyl-phenoxy)-cyclobutylmethyl]-1-methyl-urea, used for the treatment of , schizophrenia, Alzheimer's disease, attention-deficit hyperactivity disorder, hypotension, allergies, cardiovascular, gastrointestinal and psychological disorders | PFIZER INC. (US) | 2010-10-12 | — | — | US | claimed |
| US-20090131433-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2009-05-21 | — | — | US | claimed |
| US-20090069327-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-03-12 | — | — | US | claimed |
| EP-1981870-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-10-22 | — | — | EP | claimed |
| US-20080255112-A1 | Pyrimidine-Substituted Benzimidazole Derivatives as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-10-16 | — | — | US | claimed |
| CN-101213192-A | Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors | IRM LLC (BM) | 2008-07-02 | — | — | CN | claimed |
| CN-101189228-A | Bicyclic [3.1.0] heteroaryl amides as type I glycine transport inhibitors | PFIZER PROD INC (US) | 2008-05-28 | — | — | CN | claimed |
| EP-1899296-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2008-03-19 | — | — | EP | claimed |
| WO-2007092531-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-08-16 | — | — | WO | claimed |
| WO-2006136924-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-12-28 | — | — | WO | claimed |
| US-20060167270-A1 | 5-substituted 2h-pyrazone-3-carbixylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia | ARENA PHARMACEUTICALS INC. (US) | 2006-07-27 | — | — | US | claimed |
| CN-1720046-A | 5-substituted 2H-pyrazole-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related diseases such as dyslipidemia | ARENA PHARM INC (US) | 2006-01-11 | — | — | CN | claimed |
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | PROSETTA BIOSCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260070910-A1 | NITROGEN-CONTAINING HETEROCYCLIC AMIDE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2026-03-12 | — | — | US | disclosed |
| CN-1720046-A | 5-substituted 2H-pyrazole-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related diseases such as dyslipidemia | ARENA PHARM INC (US) | 2006-01-11 | — | — | CN | disclosed |
| EP-1551403-A1 | 5-SUBSTITUTED 2H-PYRAZONE-3-CARBOXYLIC ACID DERIVATIVES AS ANTILIPOLYTIC AGENTS FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS SUCH AS DYSLIPIDEMIA | Arena Pharmaceuticals, Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004032928-A1 | 5-SUBSTITUTED 2H-PYRAZONE-3-CARBOXYLIC ACID DERIVATIVES AS ANTILIPOLYTIC AGENTS FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS SUCH AS DYSLIPIDEMIA | ARENA PHARMACEUTICALS, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | NCOR1, HAVCR2, NR3C1 | HCAR3 93/4885HCAR2 214/4885TP53 1626/4885 |
| US-20090131433-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | HRH3, HRH4, HRH2 | HCAR3 19/4885HCAR2 72/4885TP53 4290/4885 |
| US-20060167270-A1 | 5-substituted 2h-pyrazone-3-carbixylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia | ACE, ACE2, AGTR2 | HCAR3 82/4885HCAR2 30/4885TP53 4817/4885 |
| US-20090069327-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | SRC, BMX, FYN | HCAR3 2399/4885HCAR2 2171/4885TP53 704/4885 |
| US-20260070910-A1 | NITROGEN-CONTAINING HETEROCYCLIC AMIDE COMPOUND AND PHARMACEUTICAL USE THEREOF | PC, CS, IDH2 | HCAR3 2573/4885HCAR2 975/4885TP53 2068/4885 |
| US-20080255112-A1 | Pyrimidine-Substituted Benzimidazole Derivatives as Protein Kinase Inhibitors | BMX, FYN, BRSK2 | HCAR3 1481/4885HCAR2 2683/4885TP53 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.